These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33159353)

  • 1. Self-management of immunomodulatory drug treatment in multiple myeloma patients.
    Cransac A; Aho S; Cosme E; Chretien ML; Favennec C; Schreder L; Boutet M; Gueneau P; Giroud M; Caillot D; Boulin M
    Eur J Cancer Care (Engl); 2021 Jan; 30(1):e13356. PubMed ID: 33159353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to immunomodulatory drugs in patients with multiple myeloma.
    Cransac A; Aho S; Chretien ML; Giroud M; Caillot D; Boulin M
    PLoS One; 2019; 14(3):e0214446. PubMed ID: 30917164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
    Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
    Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
    Raza S; Safyan RA; Lentzsch S
    Curr Cancer Drug Targets; 2017; 17(9):846-857. PubMed ID: 28201976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma.
    Barley K; He W; Agarwal S; Jagannath S; Chari A
    Leuk Lymphoma; 2016 Nov; 57(11):2510-5. PubMed ID: 26943456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
    Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
    Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.
    Dimopoulos K; Søgaard Helbo A; Fibiger Munch-Petersen H; Sjö L; Christensen J; Sommer Kristensen L; Asmar F; Hermansen NEU; O'Connel C; Gimsing P; Liang G; Grønbaek K
    Mol Oncol; 2018 Feb; 12(2):180-195. PubMed ID: 29130642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central neurotoxicity of immunomodulatory drugs in multiple myeloma.
    Patel UH; Mir MA; Sivik JK; Raheja D; Pandey MK; Talamo G
    Hematol Rep; 2015 Feb; 7(1):5704. PubMed ID: 25852850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
    Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
    Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel immunomodulatory compounds in multiple myeloma.
    Saini N; Mahindra A
    Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide.
    Montefusco V; Galli M; Spina F; Stefanoni P; Mussetti A; Perrone G; De Philippis C; Dalto S; Maura F; Bonini C; Rezzonico F; Pennisi M; Roncari L; Soldarini M; Dodero A; Farina L; Cocito F; Caprioli C; Corradini P
    Leuk Lymphoma; 2014 Sep; 55(9):2032-7. PubMed ID: 24730540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunomodulator drugs for the treatment of multiple myeloma].
    Fernández-Lázaro D; Fernández-Lázaro CI; Caballero García A; Córdova Martínez A
    Rev Med Chil; 2018 Dec; 146(12):1444-1451. PubMed ID: 30848748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
    Tzogani K; Penninga E; Schougaard Christiansen ML; Hovgaard D; Sarac SB; Camarero Jimenez J; Garcia I; Lafuente M; Sancho-López A; Salmonson T; Gisselbrecht C; Pignatti F
    Oncologist; 2018 May; 23(5):594-602. PubMed ID: 29371479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pomalidomide for multiple myeloma].
    Fouquet G; Macro M; Decaux O; Fohrer C; Guidez S; Demarquette H; Le Grand C; Prodhomme C; Renaud L; Bories C; Herbaux C; Karlin L; Roussel M; Benboubker L; Hulin C; Arnulf B; Leleu X
    Rev Med Interne; 2015 Sep; 36(9):613-8. PubMed ID: 26257103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulatory drugs in the treatment of multiple myeloma.
    Abe Y; Ishida T
    Jpn J Clin Oncol; 2019 Aug; 49(8):695-702. PubMed ID: 31187860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
    Wang Y; Yang F; Shen Y; Zhang W; Wang J; Chang VT; Andersson BS; Qazilbash MH; Champlin RE; Berenson JR; Guan X; Wang ML
    J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26582244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models.
    Cho SF; Lin L; Xing L; Li Y; Wen K; Yu T; Hsieh PA; Munshi N; Wahl J; Matthes K; Friedrich M; Arvedson T; Anderson KC; Tai YT
    Blood Adv; 2020 Sep; 4(17):4195-4207. PubMed ID: 32898244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany.
    Feiten S; Chakupurakal G; Feustel HP; Maasberg M; Otremba B; Ehscheidt P; Hensel M; Hansen R; Weide R
    Support Care Cancer; 2019 Nov; 27(11):4265-4271. PubMed ID: 30859307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
    Lacy MQ; Tefferi A
    Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.